Good Products, a provider of Enterprise Content Management (ECM) solutions and Clinical Technology Consulting for the pharmaceutical, biotechnology and medical device industries, today announced a major expansion to new UK headquarters in Nottingham, UK.
December 23, 2008-Good Products, a leading provider of Enterprise Content Management (ECM) solutions and Clinical Technology Consulting for the pharmaceutical, biotechnology and medical device industries, today announced a major expansion to new UK headquarters in Nottingham, UK. Good Products has seen a significant expansion of its business delivering electronic document management solutions to the pharmaceutical industry in 2008 and the company anticipates further growth in the healthcare industry during 2009, particularly within the small and mid-sized biopharmaceutical sector. As such the company is moving to new larger premises to continue to support its UK and international customers and to accommodate its expanding team.
Good Products' expansion and continued success reflects the continuing need from the pharmaceutical industry for streamlined and compliant regulatory
document management. The relocation reflects the significant growth experienced by Good Products since its inception in 2006. As a result of its
success the company opened a US office in Irvine, California early in 2008 to support its growing North American client base. The company's new premises in the thriving Lenton Lane business district of Nottingham will accommodate Good Product's team of up to 20 staff including new Business Development Manager Michael Brunner. The team has doubled in the last 12 months and the new offices provide the ideal base for significant expansion during 2009.
Keith Williams, CEO, Good Products, comments: "2008 has been a busy year for Good Products, which was founded as a result of identifying a growing need in the pharmaceutical, biotechnology and life sciences sectors to address regulatory and legal pressures through elements of Enterprise Content Management (ECM). During the last two years we have grown from a small company to a global leader in the area of document management and we look forward to continuing our success from these new premises."
During 2008 Good Products launched its Clinical Technology Consulting division, designed to enable biopharmaceutical sponsors and CROs to optimize their use of clinical technology. Since its inception this division has experienced significant growth inception among the sponsor and CRO communities across North America and Europe.
Good Products has advised on a number of regulatory issues including the now mandatory adoption of the eCTD for regulatory submissions. As regulatory requirements become more stringent and new standards come into practice, effective document management is addressed through the extensive g-docs suite of solutions from Good Products.
For more information on Good Products, please visit www.goodproductsEU.com or email info@goodproductsEU.com.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.